Advertisement
Canada markets close in 3 hours 29 minutes
  • S&P/TSX

    21,832.33
    -41.39 (-0.19%)
     
  • S&P 500

    5,026.78
    -44.85 (-0.88%)
     
  • DOW

    37,972.38
    -488.54 (-1.27%)
     
  • CAD/USD

    0.7304
    +0.0007 (+0.09%)
     
  • CRUDE OIL

    82.52
    -0.29 (-0.35%)
     
  • Bitcoin CAD

    87,840.59
    -506.94 (-0.57%)
     
  • CMC Crypto 200

    1,385.33
    +2.76 (+0.20%)
     
  • GOLD FUTURES

    2,336.60
    -1.80 (-0.08%)
     
  • RUSSELL 2000

    1,969.60
    -25.82 (-1.29%)
     
  • 10-Yr Bond

    4.7100
    +0.0580 (+1.25%)
     
  • NASDAQ

    15,509.31
    -203.44 (-1.29%)
     
  • VOLATILITY

    16.51
    +0.54 (+3.38%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6812
    -0.0007 (-0.10%)
     

Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.